Mar. 12, 2025 — Lupus is an autoimmune disease where the body's immune system attacks its own tissues and organs, causing inflammation and damaging organs. A new study has now shown that the ...

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...

Selena Gomez previously discussed how her lupus treatment has caused her weight to fluctuate. As social media critics pointed out the actress’ slimmer frame during Sunday’s 2025 SAG Awards ...

The Grammy-award winner was diagnosed with lupus in 2014 Nathan Vinson is the Weekend Audience Editor for PEOPLE.com, where he oversees PEOPLE's social media channels, newsletters and ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that causes widespread inflammation. It can affect the skin, joints, blood vessels, and multiple organ systems. The exact cause ...

IL-31 is a protein that drives itch and plays a role in inflammation and skin barrier dysfunction in both AD and prurigo nodularis and fibrosis in prurigo nodularis, the company states.

Nemluvio’s approved indications include atopic dermatitis in patients aged 12 years and older and prurigo nodularis in adults. The approvals are supported by two phase 3 clinical trial programs.

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for nemolizumab to treat moderate-to-severe prurigo nodularis in adults and moderate-to-severe ...

The European Commission (EC) has approved Galderma’s Nemluvio (nemolizumab) to treat both atopic dermatitis and prurigo nodularis. The drug has been authorised for use in atopic dermatitis patients ...

ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SWX:GALD) today announced that the European Commission has approved Nemluviofor both moderate-to-severe atopic dermatitis and prurigo nodularis in the ...

Dermatology specialist Galderma has FDA approval for prurigo nodularis treatment Nemluvio, one of two new drugs that it thinks will deliver blockbuster sales. Dupixent nears EU approval for rare ...

Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising the hope of a new treatment option for the rare and highly debilitating skin ...